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Background: Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody
that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell proliferation. To attempt to identify
prognostic and predictive biomarkers, retrospective analyses were used to assess tumour (HER2, VEGFR2) and serum (VEGF-C and -D,
and soluble (s) VEGFR1 and 3) biomarkers in phase 3 REGARD patients with metastatic gastric/gastroesophageal junction carcinoma.
Methods: A total of 152 out of 355 (43%) patients randomised to ramucirumab or placebo had X1 evaluable biomarker result
using VEGFR2 immunohistochemistry or HER2, immunohistochemistry or FISH, of blinded baseline tumour tissue samples. Serum
samples (32 patients, 9%) were assayed for VEGF-C and -D, and sVEGFR1 and 3.
Results: None of the biomarkers tested were associated with ramucirumab efficacy at a level of statistical significance. High
VEGFR2 endothelial expression was associated with a non-significant prognostic trend toward shorter progression-free survival
(high vs low HR¼ 1.65, 95% CI¼ 0.84,3.23). Treatment with ramucirumab was associated with a trend toward improved survival in
both high (HR¼ 0.69, 95% CI¼ 0.38, 1.22) and low (HR¼ 0.73, 95% CI¼ 0.42, 1.26) VEGFR2 subgroups. The benefit associated with
ramucirumab did not appear to differ by tumoural HER2 expression.
Conclusions: REGARD exploratory analyses did not identify a strong potentially predictive biomarker of ramucirumab efficacy;
however, statistical power was limited.
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With an annual incidence of 1.4 million new cases worldwide and a
mortality rate of 1.1 million (Ferlay et al, 2013), gastric and
gastroesophageal junction (GEJ) cancer is often diagnosed at an
advanced stage and is associated with a poor prognosis. Regimens
of cytotoxic chemotherapy commonly used as first-line therapy for
advanced gastric adenocarcinoma result in median survival
ranging from 8 to 10 months (Wagner et al, 2010). Historically,
there have been limited second-line treatment options.
Vascular endothelial growth factor (VEGF) and VEGF
receptor 2 (VEGFR2)-mediated signalling and angiogenesis
appear to have an important role in gastric cancer pathogenesis
(Lieto et al, 2008; Murukesh et al, 2010; Suzuki et al, 2010).
Ramucirumab is a human IgG1 monoclonal antibody that binds
to VEGFR2 on blood vessel endothelial cells, thereby inhibiting
VEGF ligand binding and receptor signalling, and limiting
VEGF-induced angiogenesis and migration of endothelial cells,
and slowing tumour growth (Spratlin et al, 2010). Given the
absence of approved second-line therapies for gastric adenocar-
cinoma and the need to identify new therapies, we conducted a
placebo-controlled, double-blind, phase 3 trial (REGARD) to
evaluate the safety and efficacy of ramucirumab in patients with
advanced gastric/GEJ adenocarcinoma who experienced disease
progression after first-line platinum- or fluoropyrimidine-con-
taining chemotherapy (Fuchs et al, 2014). In this trial, second-
line ramucirumab significantly prolonged overall survival (OS)
(median OS: 5.2 vs 3.8 months for ramucirumab and placebo,
respectively; hazard ratio (HR) 0.776, 95% confidence interval
(CI) 0.603–0.998, P¼ 0.047). Treatment with ramucirumab also
significantly prolonged progression-free survival (PFS; HR,
0.483; 95% CI, 0.376–0.620; Po0.0001). Ramucirumab appeared
to be well tolerated in this patient population, with similar rates
observed for most adverse events between the ramucirumab and
placebo groups.
Identification of prognostic and predictive biomarkers to better
select treatment options for patients is one of the principal goals of
translational research (TR). To date, there are no validated
predictive biomarkers for anti-angiogenic agents; however, study
of VEGF-A and VEGFR expression in resected tumour specimens
has indicated that elevated levels of some VEGF ligands and
receptors are associated with shorter survival (Fondevila et al, 2004;
Ozdemir et al, 2006; Liu et al, 2007; Osinsky et al, 2011), although
other reports disputed this association (Lee et al, 2009; Bais et al,
2014). Given these prior data, analysis of factors related to
ramucirumab mechanism of action was considered to represent an
appropriate focus for REGARD biomarker analysis. We chose to
explore candidate biomarkers in serum (soluble (s) VEGFR1, 3;
VEGF-C, -D) and tumour biopsy (VEGFR2) for their prognostic
value and potential predictive value for ramucirumab efficacy. On
the basis of prior reports, we anticipated that higher baseline
expression levels of VEGF-C, -D would be associated with poorer
survival (Ju¨ttner, et al, 2006; Cao et al, 2014). Conversely, we
anticipated higher levels of sVEGFR1 and 3 would be associated
with better survival due to their postulated function of limiting
VEGF bioavailability (Al-Husein et al, 2012). As ramucirumab acts
to limit VEGF binding to the membrane receptor, we were
interested in assessing whether ramucirumab treatment would
have its biggest effect in patients with low concentrations of
sVEGFR1 and 3 and high serum VEGF concentration. Human
epidermal growth receptor 2 (HER2) was also examined, as HER2-
positive gastric cancer now represents an important disease subset
that demonstrates sensitivity to trastuzumab, a HER2-blocking
antibody (Bang et al, 2010). Although the VEGFR and HER2
pathways differ in receptor-associated signal transduction cascades,
both result in endothelial cell proliferation. Therefore, we
anticipated that patients with both HER2-positive and HER2-
negative gastric cancer would likely respond to ramucirumab
treatment.
MATERIALS AND METHODS
Study design and patients. REGARD study design and conduct
has been reported earlier (Fuchs et al, 2014). Briefly, this global,
randomised, double-blind, placebo-controlled phase 3 trial was
conducted at 119 sites in 29 countries. Key eligibility requirements
included metastatic or nonresectable, locally advanced gastric or
GEJ adenocarcinoma; disease progression within 4 months of the
final first-line platinum- or fluoropyrimidine-containing treat-
ment, or within six months of the last dose of platinum or
fluoropyrimidine-containing adjuvant treatment; measurable dis-
ease (defined by Response Evaluation Criteria In Solid Tumors
(RECIST) version 1.0; Therasse et al, 2000) or nonmeasurable
evaluable disease; and an Eastern Cooperative Oncology Group
(ECOG) performance status score of 0 or 1 (Oken et al, 1982).
Exclusion criteria included any grade 3 or higher gastrointestinal
bleeding (National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI-CTCAE, version 4.02) within 3
months before randomisation, any arterial thromboembolic event
within 6 months prior to randomisation, or poorly controlled
hypertension.
Randomisation proceeded as described previously (2 : 1 ratio)
(Fuchs et al, 2014), with stratification by location of the primary
tumour, geographic region, and degree of weight loss during the
preceding 3 months. Patients received either intravenous ramucir-
umab (8mg kg 1) or placebo intravenously once every 2 weeks.
Treatment continued until disease progression, unacceptable
toxicity, or patient/physician decision.
Collection of pre-treatment tumour samples and baseline/post-
baseline serum samples was optional in the REGARD study.
VEGFR2 and HER2 detection and scoring. Using a well-
characterised, commercially available antibody and a specific,
selective, and sensitive immunohistochemistry (IHC) assay,
VEGFR2 protein expression was visualised in 5-micron sections
prepared from formalin-fixed paraffin-embedded (FFPE) patient
tumour specimens and quantified as previously described (Holzer
et al, 2013). HER2 protein expression was also detected by IHC,
and gene copy number was detected by fluorescence in situ
hybridisation (FISH) in FFPE tissue specimens (5-micron
sections). HER2 FISH was analysed with the PathVysion
HER2 DNA Probe Kit per manufacturer’s instructions (Abbott
Molecular, Des Plaines, IL, USA). HER2 IHC was determined with
the HercepTest per manufacturer’s instructions (Dako, Carpinteria,
CA, USA).
All biomarker assay analyses were undertaken blinded. For
VEGFR2 protein expression, the localisation of the staining was
separately scored using the H-score in tumour vessels, tumour cell
cytoplasm, and tumour nuclei, and was scored as an ordinal
variable (reported as 0, 1þ , 2þ , or 3þ ) for tumour cytoplasmic
membrane.
HER2 positivity was scored using two sets of criteria: the ToGA
trial eligibility criteria (FISH-positive or IHC3þ ), and the
more stringent criteria reported as a subgroup from ToGA
(FISH-positive and IHC2þ ; or IHC3þ ; Bang et al, 2010).
Detection of VEGF and sVEGFR in serum. Mesoscale Diag-
nostics (MSD; Rockville, MD, USA) electrochemiluminescence
(ECL) immunoassays were used for the detection of VEGF-C,
VEGF-D, sVEGFR1, and sVEGFR3 in serum. Streptavidin MSD
ELISA plates were washed with 1 Tris-buffered saline containing
10mM, Tris (pH 7.40), 150mM NaCl, and 0.1% Tween (TBST) then
blocked with 1 TBST containing 1% bovine serum albumin
(BSA). Following washes, 50 ml of 5 mgml 1 biotin-labelled mouse
VEGF-D antibody (Eli Lilly and Company, Indianapolis, IN, USA),
biotin-labelled mouse monoclonal VEGF-C antibody (Novus
Biologicals, Cat# NBP1–18626), or biotin-labelled VEGFR3
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antibody (Eli Lilly and Company) was added to respective plates
and incubated for 1 h with gentle shaking to allow binding. Next,
VEGF-D (R&D Systems, Minneapolis, MN, USA), VEGF-C
(PeproTech, Rock Hill, NJ, USA, Cat# 100-20C), or sVEGFR3
standards (Eli Lilly and Company) at varying concentrations were
diluted in assay buffer (50mM HEPES, pH 7.4; 150mM NaCl; 1%
Triton X-100; 5mM EDTA; 5mM EGTA) containing 1% BSA and
supplemented with 100 mgml 1 Heterophilic Blocking Reagent 1
(Scantibodies, Santee, CA, USA) and added to the wells of
respective plates to generate a standard calibration curve. Serum
samples were diluted and added to the plates in the same assay
buffer. All samples, calibrators, and controls were incubated at
room temperature for 2 h then the plates were washed with TBST,
and 50 ml of appropriate 1mgml 1 ruthenium-labelled detection
antibodies was added to the wells and allowed to incubate for 1 h at
room temperature. Following a final wash step, 150 ml of 2 MSD
read buffer was added, and the wells were read on a MSD SECTOR
Imager 6000 reader (Rockville, MD, USA), which recorded
ruthenium ECL.
Similar methodologies were planned for measurement of VEGF-A,
but were not carried out as it was found that platelet-derived VEGF-A
in serum causes high variability among patient samples.
Statistical analysis. VEGFR2 staining levels were summarised by
assessment type (e.g., neoplastic vessels, tumour cytoplasmic
membrane, and so on). For those assessment types where there
was a sufficient distribution of staining values, marker results were
categorised as low or high using the median H-score value as the
cutoff, or by using H-score¼ 0 vs 40. Cox models were used
to test the relationship of OS and PFS with biomarkers in a
model that included treatment, marker level (high vs low),
treatment by marker interaction, and the trial stratification factors
Table 1. Comparison of demographics, baseline disease characteristics, and efficacy outcomes in ITT and tissue TR populations
ITT population Tissue TR population
Variable, n (%)
Ramucirumab
(N¼238)
Placebo
(N¼117)
Ramucirumab
(N¼100)
Placebo
(N¼52)
Race
White 181 (76.1) 91 (77.8) 89 (89.0) 46 (88.5)
Asian 39 (16.4) 17 (14.5) 3 (3.0) 1 (1.9)
Black 4 (1.7) 2 (1.7) 3 (3.0) 1 (1.9)
Other 14 (5.9) 7 (6.0) 5 (5.0) 4 (7.7)
Geographic region
North America, Europe, Australia, New Zealand 165 (69.3) 80 (68.4) 80 (80.0) 41 (78.8)
South and Central America, India, South Africa, Jordan, Egypt, Saudi Arabia, Lebanon 55 (23.1) 29 (24.8) 19 (19.0) 11 (21.2)
Asia 18 (7.6) 8 (6.8) 1 (1.0) 0 (0)
Age group
o65 156 ( 65.5) 71 ( 60.7) 57 (57.0) 32 (61.5)
Sex
Female 69 (29.0) 38 (32.5) 29 (29.0) 21 (40.4)
ECOG performance status
0 67 (28.2) 31 (26.5) 26 (26.0) 11 (21.2)
1 171 (71.8) 85 (72.6) 74 (74.0) 41 (78.8)
2a 0 1 (0.9) 0 0
Location of primary tumour (IVRS)
Gastric 178 (74.8) 87 (74.4) 71 (71.0) 41 (78.8)
Gastroesophageal junction 60 (25.2) 30 (25.6) 29 (29.0) 11 (21.2)
Histologic type
Diffuse 96 (40.3) 44 (37.6) 41 (41.0) 21 (40.4)
Intestinal 52 (21.8) 35 (29.9) 27 (27.0) 15 (28.8)
Undetermined/unavailable 90 (37.8) 38 (32.5) 32 (32.0) 16 (30.8)
Progression-free interval on prior first-line therapyb
o6 months 154 (65.5) 83 (70.9) 61 (61.6) 36 (69.2)
X6 months 81 (34.5) 34 (29.1) 38 (38.4) 16 (30.8)
Prior treatment with trastuzumab
No 232 (97.5) 117 (100) 96 (96.0) 52 (100)
Median OS (months) (95% CI) 5.2 (4.4–5.8) 3.8 (2.8–4.7) 5.8 (5.2–7.4) 3.9 (2.5–5.8)
OS HR (95% CI) HR¼ 0.776 (0.603–0.998)c
P¼ 0.0473d
HR¼0.736 (0.497–1.091)c
P¼ 0.1261d
Median PFS (months) (95% CI) 2.1 (1.5–2.7) 1.4 (1.3–1.4) 2.7 (1.7–2.9) 1.3 (1.2–1.5)
PFS HR (95% CI) HR¼ 0.483 (0.376–0.620)c
Po0.0001d
HR¼0.495 (0.334–0.732)c
P¼ 0.0004d
Abbreviations: HR¼ hazard ratio; ITT¼ intent-to-treat; N¼ total number of patients in the corresponding arm and population; ECOG¼Eastern Cooperative Oncology Group; n¼ the number
of patients in the specified category; OS¼overall survival; CI¼ confidence interval; PFS¼progression-free survival; TR¼ translational research, with the TR population defined as the set of ITT
patients with available tissue samples.
aPatients with a PS of 2 were a protocol violation.
bDefined as the time from start of first-line treatment to disease progression on first-line. Data are not available for 4 ramucirumab arm patients, of which 3 were in the ITT population, and 1 was
in the TR population.
cHR and 95% CI obtained using a stratified Cox-proportional hazards model. One patient from the geographical region of Asia was excluded from the stratified analyses in the tissue population
due to small sample size in this stratification factor level.
dLog-rank P-value (two-sided). P-value is not adjusted for multiple testing. One patient from the geographical region of Asia was excluded from the stratified analyses in the tissue population
due to small sample size in this stratification factor level.
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(location of primary tumour, weight loss over the prior 3 months,
and geographical region) as covariates. Kolmogorov-type supre-
mum tests were used to assess proportional hazard assumptions
(Lin et al, 1993). To further explore the data, the same model was
applied using marker cutoffs from the 25th to 75th percentiles of
the range of observed marker values. Kaplan–Meier plots were
used for visualisation.
Owing to the low number of HER2-positive patients, the
relationship between clinical outcomes with HER2 status and
treatment was assessed using bean plots (vertical scatter plots of
individual efficacy outcomes by the marker-by-treatment
categories).
Assessment of the relationship between markers in serum
samples (VEGF-C, VEGF-D, sVEGFR1, and sVEGFR3) with
outcomes was performed by scatter plot due to the small number
of available samples.
No statistical corrections for multiple testing were performed.
RESULTS
Of the 355 randomised patients (2 : 1, 238 to ramucirumab and 117
to placebo) comprising the intent-to-treat (ITT) population in the
REGARD trial, 152 patients (43% of the ITT population) had at
least one evaluable IHC/FISH tissue biomarker result, comprising
the tissue TR population. The TR population for serum analysis was
32 (9% of ITT). All samples analysed were collected before treatment
initiation. The tissue population was fairly representative of the
overall ITT study population with regard to efficacy outcomes,
demographics, and baseline disease characteristics (Table 1).
VEGFR2 protein expression was assessed in tumour tissue from
147 patients (41.4% of the ITT population) using IHC; 5 patients in
the tissue TR population did not have VEGFR2 IHC results.
VEGFR2 protein expression was primarily localised to the vascular
vs the non-vascular tumour cells. VEGFR2 staining in the tumour
nuclei, cytoplasm, and cell membrane was minimal. The H-score
for tumour nuclei was 40 in 9.7% (14/144) of samples; for
cytoplasm, 22.9% (33/144) of samples had an H-score of 40.
Similarly, only 11/144 (7.6%) of samples showed cytoplasmic
membrane staining40. The number of positive samples based on
tumour cell staining was too small for correlative analyses with PFS
or OS.
VEGFR2-positive staining in tumour blood vessels (H-score
40) was observed in 86.7% of samples with a range of values
of 0–240, and H-score 25–75th percentiles of 10–80. The mean and
median H-scores and their distributions were similar in the
ramucirumab and placebo treatment arms (mean (s.d.): 49.8 (49.5)
vs 45.5 (44.5); median: 35 vs 25, ramucirumab vs placebo,
respectively).
The patients were divided into subgroups for correlative
analyses of ‘high’ and ‘low’ VEGFR2 expression based on the
median tumour vessel H-score (where the ‘high’ subgroup
includes patients with an H-score greater than or equal to
the median observed H-score across this trial, and the ‘low’
subgroup includes patients with an H-score less than the
median observed value). To assess the potential prognostic value
of VEGFR2 for OS (Figure 1A) and PFS (Figure 1B), the
subgroups with high vs low VEGFR2 levels within the
placebo arm were compared. The HR for PFS was 1.65 (95%
CI 0.84–3.23, P¼ 0.1821), suggesting high VEGFR2 levels might
be associated with earlier progression in the absence of
treatment. However this finding was not statistically significant.
Further data are needed to support an association of high
VEGFR2 levels with a poorer prognosis.
The potential predictive value of VEGFR2 protein was also
assessed by modelling both treatment arms. In both high and low
VEGFR2 protein-staining subgroups, there was a trend toward
improved OS and PFS in the ramucirumab arm compared with the
placebo arm, consistent with the results in the overall trial ITT
population. The effect associated with ramucirumab appeared
more pronounced in patients with high VEGFR2 expression (OS
HR¼ 0.69, 95% CI¼ 0.38, 1.22; PFS HR¼ 0.35, 95% CI¼ 0.20,
0.59). However, there was evidence against the proportional
hazards assumption (P¼ 0.005) for OS comparison between
treatment arms in the high VEGFR2 subgroup, and statistical
power to characterise the interactions between VEGFR2 expression
and treatment with ramucirumab was limited for all analyses
(Figure 2A–D, Table 2). To further explore the data, similar
analyses were performed using other cutpoints to divide the
patients into high and low VEGFR2-expressing subgroups: H-score
of 0 vs 40 and the 25th to the 75th percentile of the VEGFR2
H-score values observed (data on file). For both PFS and OS, an
HR o1 in both the high and low VEGFR2 protein expression
subgroups suggested that patients treated with ramucirumab
generally had benefit over the patients treated on the placebo
arm, regardless of the cut-point examined. Together, these results
suggest that all VEGFR2 IHC-defined subgroups of patients are
likely to benefit from ramucirumab treatment; however, because of
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Figure 1. Kaplan–Meier plot of OS and PFS by high and low VEGFR2
groups in the placebo arm. Patients from the placebo arm with
VEGFR2 IHC results from neoplastic vessels were dichotomised into the
high and low subgroups, based on their individual VEGFR2 levels
relative to the median level for the population (all patients across both
arms with available results) (H-score median¼35). Kaplan–Meier plots
for (A) OS and (B) PFS are shown. Inset tables give median survival
times (months) and 95% CIs. Abbreviations: CI, confidence interval; HR,
hazard ratio; n, number of patients; VEGFR2, vascular endothelial
growth factor receptor 2.
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limited sample size, these results should be interpreted with
caution.
Assessment of tumour HER2 expression by IHC and FISH
testing was performed on the tissue samples, with at least one result
obtained from 147 of the 152 patients in the TR population. (The
five patients without HER2 results are a different subset than those
without VEGFR2 results.) HER2 positivity, as characterised by
either FISH-positive or IHC3þ , was observed in 21 (14%)
patients. Scatter plots comparing OS and PFS by treatment arm
and HER2 status (Figure 3A and B) indicate no apparent lack of
benefit of ramucirumab in patients with HER2-positive tumours,
or conversely, among patients with HER2-negative tumours.
However, there was some indication, albeit very limited by sample
size in these subgroups, of ramucirumab benefit compared with the
placebo arm in both HER2-positive and -negative tumours.
HER2 positivity was defined by more rigorous criteria: both
FISH-positive and IHC2þ , or IHC3þ , was observed in 12 (8%)
patient specimens, 3 in the placebo arm and 9 in the ramucirumab
arm. This sample size is too small to draw any conclusions;
however, as with the less-stringent HER2-positive criteria, there
was no apparent lack of benefit for the HER2-positive patients
(data not shown).
Measurement of circulating VEGF-C, VEGF-D, VEGFR1, and
VEGFR3 was carried out in pre-treatment patient serum samples.
Sample collection for biomarkers was initially performed only at
specific sites, but then later added to other sites. Therefore, the
population of patients with serum samples is limited (9.0% of ITT
population) and did not tightly mirror the ITT population for
demographics or efficacy outcomes. Scatter plots were used to
summarise the relationship between analyte expression and
efficacy outcomes (OS and PFS; Figure 4A–H). In each case, no
apparent relationship between serum protein quantity and
treatment efficacy was observed.
DISCUSSION
Patient serum and tumour samples obtained during the REGARD
metastatic gastric/GEJ phase 3 clinical trial were analysed for
correlation of biomarker expression and ramucirumab-associated
efficacy. The analyses focused on markers thought likely to be
associated with ramucirumab efficacy, such as VEGF ligands and
receptors, and gastric cancer biology. As REGARD was a
monotherapy study, any differential effect of biomarker level on
treatment efficacy could be attributed to ramucirumab.
The present exploratory research in the cohort of patients with
available tissue and serum specimens failed to identify a candidate
biomarker(s) that would facilitate selection of patients more likely
to benefit from ramucirumab. Data did indicate that the benefit of
ramucirumab may be more pronounced in patients with high
VEGFR2 expression. This result further advances the hypothesis
that the VEGF/VEGFR2 pathway is integral to tumour growth and
targeting angiogenesis is a promising strategy. Importantly, the
REGARD trial was not powered for this retrospective analysis,
multiple markers were explored, and thus these findings should be
explored in further prospective studies.
The IHC results confirmed the minimal expression of VEGFR2
in gastric tumour cells and the substantial expression of VEGFR2
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Figure 2. Kaplan–Meier plot of OS and PFS by treatment arm in the VEGFR2 high and low groups. Patients with VEGFR2 IHC results from
neoplastic vessels were dichotomised into the high and low subgroups, based on their individual VEGFR2 levels relative to the median level for the
population (H-score median¼35). Kaplan–Meier plots for OS in patients in the (A) high VEGFR2 group (H-scoreX35) and (B) low VEGFR2 group
(H-scoreo35), and for PFS in the (C) high VEGFR2 group and (D) low VEGFR2 group are shown. Inset tables give median survival times (months)
and 95% CIs. Abbreviations: CI, confidence interval; HR, hazard ratio; n, number of patients; PBO, placebo; RAM, ramucirumab; VEGFR2, vascular
endothelial growth factor receptor 2.
BRITISH JOURNAL OF CANCER Biomarkers for ramucirumab-treated gastric cancer
978 www.bjcancer.com |DOI:10.1038/bjc.2016.293
in neoplastic tumour vascular endothelium reported earlier by
others (Smith et al, 2010). This observation is consistent with the
presumed mechanism of action of ramucirumab; that is, targeting
the VEGFR2 expressed on the vascular endothelium. The present
data suggest an association between high VEGFR2 levels and worse
prognosis (in particular PFS) in the placebo arm in this study.
Importantly, the benefit of ramucirumab appears to be more
pronounced in this same subgroup of patients with high VEGFR2
expression that is otherwise characterised by poor prognosis.
Another recent study examining the VEGF/VEGFR pathway also
observed a link between survival and differences in levels of these
factors. In this case, Ock et al (2015) observed worse OS was
correlated with a high VEGF/sVEGFR2 ratio as measured in the
pre-treatment serum of gastric cancer patients.
Further evaluation is also required to define other biomarkers of
angiogenesis and endothelial cell biology that may predict
ramucirumab efficacy. Tumour blood vessels are known to be
abnormal compared to non-tumour blood vessels and charac-
terised by disorganised architecture, abnormal barrier function,
and structural abnormalities of the basement membrane (Dvorak,
2003). However, whereas it is established that aberrant signalling
occurs in the tumour, it remains to be determined whether the
endothelial cells in tumour blood vessels are also characterised by
specific gene mutations or aberrant RNA or protein expression.
Although conclusions are limited by small sample numbers,
assessment of HER2 expression by IHC and FISH testing found no
trend of an association between HER2 positivity and efficacy of
ramucirumab; however, the expected low number of HER2-
positive specimens was observed. HER2 positivity, defined by a
patient sample that was either FISH-positive or IHC3þ , was
observed in 21 (14%) patients. This percentage of HER2-positive
patients is within the range of the overall incidence in gastric
cancer reported in recent retrospective analyses of surgical
specimens in advanced gastric cancer (10–17.4%; Ieni et al, 2013;
Sheng et al, 2013; Betts et al, 2014).
Recently, whole-genome sequencing, comprehensive molecular
profiling, and analysis of somatic copy-number alterations have
been used to identify new driver mutations/alterations in gastric
cancer tumour cells, although not the endothelium of tumour
blood vessels supplying these tumours. These studies highlighted
the molecular complexity of gastric cancer cells, but still leave
many unanswered questions regarding the roles of the micro-
environment and tumour vasculature (Lawrence et al, 2014;
Lee et al, 2014; Wang et al, 2014). Notably, The Cancer Genome
Atlas (TCGA) analysis of gastric cancer did identify VEGF
Table 2. Overall and progression-free survival in VEGFR2 high and low groups as defined by VEGFR2 median and zero H-score
cutpoints
High VEGFR2 Low VEGFR2
Ramucirumab Placebo Ramucirumab Placebo
Median H-score¼35
N 49 23 46 25
Median OS (months; 95% CI) 6.6 (5.0, 9.3) 2.3 (1.5, 4.8) 5.6 (3.4, 7.1) 4.5 (2.6, 6.7)
OS treatment HR (95% CI) 0.69 (0.38, 1.22) 0.73 (0.42, 1.26)
Median PFS (months; 95% CI) 2.8 (1.5, 4.1) 1.3 (1.1, 1.3) 2.2 (1.4, 2.8) 1.9 (1.3, 2.7)
PFS treatment HR (95% CI) 0.35 (0.20, 0.59) 0.73 (0.42, 1.27)
H-score¼0
N 84 40 11 8
Median OS (months; 95% CI) 5.8 (5.0, 7.3) 3.7 (1.8, 5.7) 5.6 (1.3, —) 4.0 (0.3, 13.2)
OS treatment HR (95% CI) 0.71 (0.46, 1.10) 0.67 (0.24, 1.87)
Median PFS (months; 95% CI) 2.8 (1.6, 2.9) 1.3 (1.2, 1.9) 1.9 (1.3, 4.3) 1.4 (0.3, 5.6)
PFS treatment HR (95% CI) 0.49 (0.32, 0.75) 0.67 (0.25, 1.78)
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; N¼ number of patient samples in each subgroup; OS¼overall survival, PFS¼progression-free survival; VEGFR2¼ vascular
endothelial growth factor receptor 2.
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Figure 3. OS plot and PFS survival plot by HER2 positivity and
treatment arm. (A) OS times and (B) PFS times are shown for patients
grouped by HER2 classification and treatment arm. Open circles
indicate patients with censored OS/PFS times and solid dots indicate
patients with uncensored times. Horizontal lines and inset table show
Kaplan–Meier median survival times (months) and 95% CIs.
Abbreviations: HER2, human epidermal growth factor receptor 2; n,
number of patients; OS, overall survival; PBO, placebo; PFS,
progression-free survival; RAM, ramucirumab.
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Figure 4. Scatter plots of OS and PFS vs biomarkers VEGF-C, VEGF-D, VEGFR1, and VEGFR3. OS values were plotted for each patient by serum
concentration of (A) VEGF-C, (C) VEGF-D, (E) VEGFR1, and (G) VEGFR3. PFS was similarly plotted for each patient by serum concentration of (B)
VEGF-C, (D) VEGF-D, and (F) VEGFR1, and (H) VEGFR3. Data from patients treated with ramucirumab are shown with a red circle (n¼ 18, except
VEGFR1 where n¼17); data from patients treated with placebo are indicated by a blue diamond (n¼ 14). Censored observations are indicated
with open symbols. The x-axis is discontinuous for plots A, B, E, and F.
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amplifications in a subset of tumours (Lawrence et al, 2014). Other
approaches using in vitro transcription factor activity profiling and
integrative genomics resulted in the identification of three
categories of factors/pathways involved: highly activated signalling
pathways resulting from mutations; constitutively activated stress
responsive pathways; and consistently downregulated nuclear
receptor responsive factors. This functional profiling illustrates
the complexity of gastric cancer biology and might help in
discriminating therapeutic targets and signalling interactions for
future studies (Periasamy et al, 2014). Thus, despite the rapidly
evolving knowledge on gastric cancer cell biology, the same
progress has not been made in the investigation of aberrant
signalling in the vasculature. Therefore, limited information on
predictive vessel biomarkers exists that could impact patient
selection for treatments targeted at VEGFR2.
The present retrospective analyses have limitations. First, with the
exception of HER2, the biomarkers that were examined were limited
to the VEGF/VEGFR pathway. A broader examination of angiogenic
factors would be beneficial, especially in light of evidence suggesting
PDGF-BB (and perhaps other isoforms) may cause resistance to
anti-VEGF therapy (Al-Husein et al, 2012). VEGFR2 expression by
IHC is an exploratory biomarker and some analytical and
interpretive matters remain to be resolved. It also remains to be
determined whether there are differences in VEGFR2 expression
between primary tumour and metastases, and whether VEGFR2
expression changes with time. Samples were collected in only a
subset of patients leading to a potential selection bias and limiting
the power of statistical analyses. The efficacy outcomes found in the
present analyses will be re-examined in other recent phase 3
ramucirumab studies (REVEL, RAINBOW and RAISE; Garon et al,
2014; Wilke et al, 2014; Tabernero et al, 2015) that had greater
participation in sample collection, and thus have the potential of
generating a more robust data set. In addition, upcoming gastric
cancer clinical trials involving ramucirumab treatment combinations
and dosing schedules may yield more information about relation-
ships between biomarker expression and efficacy outcomes.
To date, no reproducible predictive blood or tissue biomarkers
have been identified despite years of extensive biomarker research
across multiple solid tumour types in patients treated with anti-
angiogenic agents (Shojaei, 2012). Although the present retro-
spective exploratory analysis of VEGFR2 and HER2 expression in
available tumour tissue samples from the REGARD phase 3 trial
also did not reveal a biomarker identifying patients who do and do
not benefit from ramucirumab in metastatic gastric and GEJ
adenocarcinoma, the benefit of this drug could be more
pronounced in patients with high VEGFR2 expression. Further
studies are needed to investigate the predictive potential of high
VEGFR2 expression in patients with advanced gastric cancer
treated with ramucirumab.
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